Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Assets Average (2021 - 2026)

Krystal Biotech's Assets Average history spans 6 years, with the latest figure at $1.4 billion for Q1 2026.

  • On a quarterly basis, Assets Average rose 28.19% to $1.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 billion, a 28.19% increase, with the full-year FY2025 number at $1.2 billion, up 27.5% from a year prior.
  • Assets Average hit $1.4 billion in Q1 2026 for Krystal Biotech, up from $1.3 billion in the prior quarter.
  • Over the last five years, Assets Average for KRYS hit a ceiling of $1.4 billion in Q1 2026 and a floor of $545.1 million in Q1 2023.
  • Historically, Assets Average has averaged $869.7 million across 5 years, with a median of $835.8 million in 2024.
  • Biggest five-year swings in Assets Average: soared 64.91% in 2022 and later dropped 12.3% in 2023.
  • Tracing KRYS's Assets Average over 5 years: stood at $567.4 million in 2022, then skyrocketed by 41.76% to $804.4 million in 2023, then increased by 26.7% to $1.0 billion in 2024, then rose by 26.29% to $1.3 billion in 2025, then increased by 6.09% to $1.4 billion in 2026.
  • Business Quant data shows Assets Average for KRYS at $1.4 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.